[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carotid-atherosclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carotid-atherosclerosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,75,102,125,151,172,192,250,280,302,328],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100615903","3d-contrast-enhanced-microvascular-ultrasound-of-carotid-atherosclerosis-for-the-detection-of-carotid-plaque-neo-revascularisation-100615903",false,"NCT07298655","3D Contrast Enhanced Microvascular Ultrasound of Carotid Atherosclerosis for the Detection of Carotid Plaque Neo-Revascularisation.","Carotid Neo3D","Inclusion Criteria:\n\n1. Age\\>18 years old.\n2. Previously consent for participation in the SECURE trial and have undergone carotid CEUS.\n3. Found to have at least one carotid plaque present on carotid CEUS.\n4. Able to give informed consent to participate in the study and its procedures.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years old.\n2. Unable to provide informed consent to participate in the study and its procedures.\n3. Allergy to microbubble contrast agents.\n4. Known pregnancy.","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","Atherosclerotic plaques, the build-up of fatty materials within our arteries, can develop over a long period of time without causing any symptoms.\n\nThese plaques may continue to grow and rupture causing narrowing and blockages of the blood vessels. This can lead to serious cardiovascular disease such as a heart attack or stroke causing over 160,000 deaths each year.\n\nLots of research has been done on why particular groups of people may develop atherosclerosis and controlling risk factors such as diabetes and high blood pressure go a long way to reduce people's risks. However, despite the treatments we have available and controlling these risk factors, some people unfortunately still go on to develop a potentially serious disease.\n\nFurther research has shown us that certain plaques in the blood vessels may be more vulnerable to rupturing compared to others. So far we know that plaques with thin caps, soft centres or those that are able to grow their own tiny blood vessels are more likely to rupture. We have now started to develop new imaging methods to try and help us detect these vulnerabilities. The hope is by being able to detect more vulnerable plaques we may be able to treat these earlier and therefore more effectively.\n\nThere are different scans available to try and visualise the tiny vessels within these plaques in the neck arteries. These include, MRI (a Magnetic Resonance Imaging scan, taking pictures using a small tunnel), CT (Computed Tomography, uses a ring-shaped machine to take pictures), and ultrasound. Ultrasound has the benefit of being free of ionising radiation and iodinated contrast, therefore posing less risk to patients. However, current ultrasound uses 2D ultrasound. Although this has shown promising results, our blood vessels and any plaques are 3D structures so we don't get to see the whole plaque using 2D imaging and therefore may miss important information. The available 3D probes in use at the moment are not able to visualise the tiny vessels accurately enough.\n\nThis study uses a different 3D ultrasound probe and ultrasound machine that is able to produce many more images than our usual probes. By taking images with this probe and using offline computer programmes to track the contrast through structures we hope that this system will be able to give us a visualisation of the whole plaque enabling us to detect any new blood vessels more accurately.",[26,27,28],"Carotid Atherosclerosis","Ultrasound","Plaque Neovascularization",[30,31,32],"Carotid atherosclerosis","Carotid Ultrasound","Plaque Neovascularisation","RECRUITING","2026-04-09",{"date":36,"type":37},"2026-04-13","ACTUAL",{"date":39,"type":37},"2025-10-16",{"date":41,"type":20},"2026-09-30",{"name":43,"class":44},"London North West Healthcare NHS Trust","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100503691","canf-comb-ii-pet-mr-in-atherosclerosis-multisite-100503691","NCT05838547","CANF-Comb-II PET-MR in Atherosclerosis Multisite","PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With Cu[64]-25%-CANF-Comb-II","Inclusion Criteria:\n\n* Adults, 18 years of age or older\n* Asymptomatic carotid artery stenosis patients who have undergone carotid Doppler\u002Fultrasound imaging or other carotid imaging which have demonstrated a ≥ 60% diameter carotid artery stenosis.\n* The treating surgeon has planned either treatment with optimal medical therapy (OMT) alone, or OMT and carotid endarterectomy (CEA) surgical intervention.\n\nExclusion Criteria:\n\n* Inability to receive and sign informed consent.\n* Patients with an unstable clinical condition that in the opinion of the Sponsor-Investigator or designee precludes participation in the study.\n* Inability to tolerate up to 60 minutes in a supine position with arms down at sides for PET-MR imaging.\n* Prior history of CEA or carotid artery stent procedure on the ipsilateral side.\n* Past medical history of TIA or stroke within the last 6 months.\n* Unwilling to comply with study procedures and\u002For unable to be available for the duration of the study outlined in the protocol.\n* Contraindications to MR imaging (pacemaker, brain aneurysm clips, shrapnel, claustrophobia, etc.).\n* Currently pregnant or lactating. All female subjects of childbearing potential must have a documented negative pregnancy test (serum or urine hCG) performed within 24 hours immediately prior to the administration of 64Cu-25%-CANF-Comb or documented post-menopausal defined as the cessation of menses for ≥ 12 months or documentation of having a bilateral oophorectomy and\u002For hysterectomy.",{"count":54,"type":20},80,"OBSERVATIONAL","The goal of this observational study is to learn more about plaque biology in asymptomatic carotid artery stenosis (ACAS) patients through imaging. The main questions it aims to answer are:\n\n* To determine the ability of 64Cu-CANF-Comb positron emission tomography (PET) to risk stratify ACAS patients for stroke event, to include transient ischemic attack or remote ipsilateral intervention.\n* To further understand the role of Natriuretic Peptide Receptor C (NPRC) in the evolution of carotid atherosclerosis.\n\nParticipants will be asked to undergo a carotid PET-magnetic resonance imaging (MRI) examination to assess whether the carotid atherosclerosis uptake of 64Cu-CANF-Comb as measured by PET-MRI correlates with patient outcomes (stroke, transient ischemic attack, or remote ipsilateral intervention).",[26,58,59],"Asymptomatic Carotid Artery Stenosis","Carotid Artery Atheroma",[61,62,63,64],"Stroke","TIA","Vascular Disease","Cardiovascular Disease","2026-03-19",{"date":67,"type":37},"2026-03-23",{"date":69,"type":37},"2023-03-21",{"date":71,"type":20},"2027-05-31",{"name":73,"class":44},"Washington University School of Medicine",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100500789","prediction-of-cerebral-hyperperfusion-syndrome-after-carotid-revascularization-using-deep-learning-100500789","NCT05800821","Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning","Inclusion Criteria:\n\n1. Age between 30 and 80 years.\n2. Occlusive-stenotic lesion of the carotid arteries with indications for carotid revascularization.\n\nExclusion Criteria:\n\n1. Systemic vasculitis.\n2. Cerebral vessel aneurysms.\n3. Arteriovenous malformation of the brain.\n4. Primary brain tumor (including metastatic lesions).\n5. Epilepsy.\n6. History of traumatic brain injury.\n7. Demyelinating diseases of the central nervous system.\n8. History of neuroinfection.\n9. Atrial fibrillation.\n10. Frequent supraventricular or ventricular extrasystoles.\n11. Chronic heart failure with left ventricular ejection fraction less than 40%.\n12. Chronic kidney disease with estimated glomerular filtration rate less than 45 mL\u002Fmin\u002F1.73 m².\n13. Presence of an implanted cardioverter-defibrillator or pacemaker.\n14. Presence of contraindications to the medical use of iodine-containing radiographic contrast agents.\n15. Patient's unwillingness to continue participating in the study.\n16. Absence of a temporal acoustic window for transcranial Doppler ultrasonography.","30 Years","80 Years",{"count":84,"type":20},500,"Cerebral hyperperfusion syndrome (CHS) was initially described as a clinical complication following carotid endarterectomy (CEA), but it may occur after both CEA and carotid artery stenting. It is characterised by throbbing ipsilateral frontotemporal or periorbital headache, and sometimes diffuse headache, eye and facial pain, vomiting, confusion, macular oedema, visual disturbances, focal motor seizures with frequent secondary generalisation, focal neurological deficits, and intracerebral or subarachnoid haemorrhage.\n\nKnowledge of CHS among physicians remains limited. Most studies report an incidence of 1-3% after carotid endarterectomy. CHS is most common in patients with increases of more than 100% in cerebral perfusion compared with baseline after carotid revascularization, and is rare in patients with perfusion increases of less than 100% compared with baseline.\n\nThe pathophysiological mechanism of CHS is only partially understood. The chronic low-flow state induced by severe carotid disease results in compensatory dilation of cerebral vessels distal to the stenosis, as part of the normal autoregulatory response to maintain adequate cerebral blood flow (CBF). In this chronically dilated state, the vessels lose their ability to autoregulate vascular resistance in response to changes in blood pressure. Dysautoregulation has been shown to be proportional to the duration and severity of chronic hypoperfusion. After revascularization and reperfusion, impaired cerebral autoregulation may contribute to a cascade of intracranial microcirculatory changes, with an inability to respond adequately to the augmentation of CBF following carotid recanalization.\n\nAlthough most patients present with mild symptoms and signs, progression to severe and life-threatening complications can occur if CHS is not recognised and treated promptly. Because CHS is diagnosed on the basis of several non-specific signs and symptoms, patients may be misdiagnosed as having one of the better-known causes of perioperative complications, such as thromboembolism.",[87,26,88,89],"Carotid Artery Diseases","Carotid Artery Stenosis","Cerebral Hyperperfusion Syndrome",[89,91,61,92],"Carotid Stenosis","Deep Learning","2025-11-20",{"date":95,"type":37},"2025-11-25",{"date":97,"type":37},"2023-05-03",{"date":99,"type":20},"2030-05-03",{"name":101,"class":44},"State Institution \"Republican Scientific and Practical Center\" Cardiology, Belarus",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":45},"100607797","microflow3d---non-invasive-mapping-of-coronary-arteries-and-the-cerebral-vascular-network-using-3d-ultrasound-localization-microscopy-in-patients-with-atherosclerosis-prior-to-carotid-endarterectomy-surgery-100607797","NCT07193225","Microflow3D - Non-invasive Mapping of Coronary Arteries and the Cerebral Vascular Network Using 3D Ultrasound Localization Microscopy in Patients With Atherosclerosis Prior to Carotid Endarterectomy Surgery","Non-invasive Mapping of Coronary Arteries and the Cerebral Vascular Network Using 3D Ultrasound Localization Microscopy in Patients With Atherosclerosis Prior to Carotid Endarterectomy Surgery - Microflow3D","Microflow3D","Inclusion Criteria:\n\n* Patients with asymptomatic carotid stenosis, without recent stroke, and scheduled for carotid endarterectomy within the next 30 days.\n* Age ≥ 18 years.\n* Beneficiary of a social security system or equivalent coverage.\n* Signed informed consent.\n* Patients already enrolled in another biomedical research study may also participate in this study.\n\nExclusion Criteria:\n\n* Contraindication to the use of the ultrasound contrast agent SonoVue®: known hypersensitivity to the active substance or to any of the following excipients: Macrogol 4000; Distearoylphosphatidylcholine; Sodium dipalmitoylphosphatidylglycerol; Palmitic acid.\n* Allergy to ultrasound gel.\n* Refusal or inability (linguistic or psychological) to sign the informed consent form.\n* Subject to legal protection measures, such as guardianship (in accordance with Article L1122-2 of the French Public Health Code).\n* Pregnant or breastfeeding women cannot participate in this study.",{"count":111,"type":20},37,[23],"There is a need to simplify the assessment of coronary and cerebral vascular networks in patients selected for carotid endarterectomy in order to prevent potential complications during and after surgery. A non-invasive, non-ionizing 3 dimension mapping of these networks would provide a remarkable benefit for patients.",[26],"NOT_YET_RECRUITING","2025-09-18",{"date":118,"type":37},"2025-09-25",{"date":120,"type":20},"2025-11-01",{"date":122,"type":20},"2027-11-30",{"name":124,"class":44},"French Cardiology Society",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":45},"100366051","impact-of-treating-severe-periodontitis-on-inflammatory-activity-of-atheromatous-plaques-in-patients-with-acute-myocardial-infarction-ami-100366051","NCT04046237","Impact of Treating Severe Periodontitis on Inflammatory Activity of Atheromatous Plaques in Patients With Acute Myocardial Infarction (AMI)","PAROCARD","Inclusion Criteria:\n\n* Patients hospitalized for an acute myocardial infarction and included in the Frenchie registry\n* Score ≥ 5 on the screening questionnaire for periodontitis\n* Six teeth at least (excluding wisdom teeth)\n* Consent signature\n* Affiliation to a French medical insurance (Sécurité Sociale)\n\nExclusion Criteria:\n\n* Patients with diseases,other than cardiovascular and diabetes, known to change the periodontal state such as AIDS, rheumatoid arthritis, Chediak-Higashi syndrome, Papillon-Lefèvre\n* Systemic antibiotic therapy\\> 48 hours in the 3 months prior to inclusion\n* Acute heart failure\n* Uncontrolled ventricular rhythm disorders\n* Impossibility for the patient to attend follow-up visits\n* Impossibility to maintain the extended position for 20 minutes\n* Immunosuppressive therapy\\> 1 month in the 6 months prior to inclusion\n* Pregnancy, breastfeeding\n* Known hypersensitivity to chlorhexidine, povidone, 18-fluoro-deoxyglucose","70 Years",{"count":134,"type":20},210,[23],"Multicenter randomized clinical trial with two arms in patients hospitalized for an AMI nested in the Frenchie registry. Periodontal therapy is performed by periodontists in the intervention group versus treatment by dental surgeons as part of their usual practice in the control group.\n\nFor the intervention group, periodontal management will be carried out for a maximum of 6 months after randomisation, prolonged by a follow-up of 6 months including a maintenance visit at M9.\n\nAll patients will have an FDG-PET at M0 and M12 for evaluation of inflammation on carotid atherosclerotic plaques.",[138,139,26],"Acute Myocardial Infarction","Severe Periodontitis",[138,139,141,26],"FDG-PET","2025-09-01",{"date":144,"type":37},"2025-09-08",{"date":146,"type":37},"2019-08-02",{"date":148,"type":20},"2028-08",{"name":150,"class":44},"Assistance Publique - Hôpitaux de Paris",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":171,"locationsCount":45},"100403751","phase-1-pet-detection-of-ccr2-in-human-atherosclerosis-100403751","NCT04537403","PET Detection of CCR2 in Human Atherosclerosis","Inclusion Criteria: Normal Volunteers: 18-40 years of age, non smoker, no history of diabetes, hypertension, or hyperlipidemia. Patients: 50-89 years of age, adequate nutritional status, with or without smoking history, diabetes, hypertension, and hyperlipidema. Both asymptomatic and symptomatic patients with known carotid artery atherosclrosis \\>70% and scheduled to undergo surgery. Advanced peripheral artery disease.\n\n\\-\n\nExclusion Criteria:Inability to receive and sign informed consent. Currently enrolled in another study. Patients who have type 1 diabetes or are in septic shock, receiving steroid therapy, recent history of heavy alcohol consumption, (male \\>2 drinks per day, and female \\> 1 drink per day. following extreme diets like Atkins or South Beach diet or with Stage 4 chronic renal failure. Patients with unstable clinical condition that in the opinion of the PI precludes participation in the study. Inability to tolerate 60 minutes in a supine position with arms down at sides. Contraindications to MR imaging, (pacemaker, brain aneurysm clips, shrapnel, etc. Positive pregnancy test or lactating. Have another conditions such as cancer or autoimmune\u002Finflammatory diseases, e.g. rheumatoid arthritis or multiple sclerosis that are known to have increased expression of CCR2.\n\n\\-",true,"89 Years",{"count":160,"type":20},100,[162],"PHASE1",": Use of novel radio-pharmaceutical 64CUDOTA-ECL1i to evaluate arterial atherosclrosis",[26],"2025-07-28",{"date":167,"type":37},"2025-08-01",{"date":169,"type":37},"2020-10-01",{"date":142,"type":20},{"name":73,"class":44},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":45},"100532563","shear-wave-elastography-for-carotid-atherosclerotic-plaques-100532563","NCT06214429","Shear Wave Elastography for Carotid Atherosclerotic Plaques","Evaluation of Atherosclerotic Carotid Plaque Stiffness by Shear Wave Elastography, Greyscale Median, Magnetic Resonance Imaging and Histopathological Analysis: Diagnostic Test Study","Inclusion Criteria:\n\n* Patients with atherosclerotic carotid plaques that develop stenosis superior to 50%.\n\nExclusion Criteria:\n\n* Previous cervical surgery;\n* Previous cervical radiotherapy;\n* Stenosis caused by vascular inflammatory diseases;\n* Pregnant women;\n* High carotid bifurcation (inaccessible by vascular ultrasound linear probe);\n* Posterior acoustic shadowing that impair morphological evaluation of the plaque.",{"count":180,"type":20},43,"The goal of this prospective diagnostic accuracy cohort study is to compare the accuracy of carotid atherosclerotic plaques stiffness assessed by shear wave elastography (SWE) with greyscale median values (GSM), magnetic resonance imaging (MRI) and histopathological findings in patients with carotid atherosclerotic plaques causing stenosis above 50%, symptomatic or not.\n\nThe main question it aims to answer is: is the plaque stiffness correlatable with GSM values, MRI findings or histopathological findings? Participants will be subjected to a vascular ultrasound study in which the SWE and GSM will be assessed. The second imaging modality for stenosis confirmation will be MRI and patients with confirmed symptomatic stenosis above 50% or assymptomatic stenosis above 70% will be considered for surgery intervention (endarterectomy or angioplasty). Patients that undergo endarterectomy will have the carotid plaques subjected to a histopathological study. The study will not arbitrate about the treatment decision.",[26],"2025-04-02",{"date":185,"type":37},"2025-04-06",{"date":187,"type":37},"2023-03-01",{"date":189,"type":20},"2025-12-31",{"name":191,"class":44},"UPECLIN HC FM Botucatu Unesp",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":202,"briefSummary":203,"conditions":204,"keywords":210,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":45},"100557713","coated-or-chewable-aspirin-and-a-hybrid-strategy-to-mitigate-adverse-effects-of-air-pollution-in-stable-atherosclerotic-disease-100557713","NCT06541691","Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease","Coated or Chewable Aspirin in Patients with Established Atherosclerotic Disease and a Hybrid Strategy to Mitigate the Adverse Effects of Air Pollution: the COATED-AIR Randomized Clinical Trial","COATED-AIR","Inclusion Criteria:\n\n* Adult patients (≥18 years) with documented ASCVD defined as at least one of the following:\n\n  * Coronary artery disease (CAD):\n\n    1. Previous or recent documented type I myocardial infarction \\*(if not specified, will be assumed as type I)\n    2. History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery)\n    3. History of obstructive CAD (\\>50% stenosis) documented by coronary computed tomography (CT) or conventional angiography\n  * Peripheral arterial disease (PAD):\n\n    1. Previous or recent acute ischemic limb event (\\>7 days prior)\n    2. History of previous endovascular\u002Fsurgical lower or upper extremities revascularization for an atherosclerotic cause\n    3. History of ulcer or lower extremities amputation due to ASCVD.\n  * Carotid arterial diseases:\n\n    1. History of previous endovascular\u002Fsurgical carotid artery revascularization for atherosclerotic causes\n    2. History of \\> 50% carotid artery stenosis based on documented imaging tests (Duplex US, CT angiography, magnetic resonance angiography, or conventional angiography)\n  * Ischemic stroke:\n\n    1. History of recent or previous documented ischemic stroke not due to atrial fibrillation, endocarditis, or systemic hypoperfusion\u002Fhypotension, being treated with low-dose aspirin\n* Inhabitant of Tehran province\n* Willing to participate and able to provide written informed consent\n\nExclusion Criteria:\n\n* Being within 72 days of acute\u002Funstable atherosclerotic cardiovascular events (acute myocardial infarction, acute limb event, and acute ischemic stroke), or within 72 hours of revascularization.\n* Patients receiving triple antithrombotic therapy\n* History of upper gastrointestinal bleeding within the past 30 days\n* History of intracranial hemorrhage within the past 30 days\n* End-stage kidney disease with estimated creatinine clearance \\\u003C 15 mL\u002Fmin, or undergoing hemodialysis or peritoneal dialysis\n* Known comorbidities associated with poor prognosis (e.g., metastatic cancer) in conjunction with an estimated life expectancy of less than one year according to the treating clinician\n* Any other conditions that make the participants unsuitable for recruitment or follow-up (e.g., illiteracy)\n* Not having aspirin as part of the planned durable treatment regimen\n* Inability to receive\u002Fread text messages\u002Fphone calls by personal mobile phone (or that of a caregiver who lives with the patient and is willing to relay messages)\n\n  * The full list of exclusion criteria is provided in the study protocol",{"count":201,"type":20},3000,[23],"Although both enteric-coated and plain formulations of aspirin are being used commonly, there are no high-quality comparisons between these formulations with respect to clinical efficacy outcomes in patients with atherosclerotic cardiovascular diseases (ASCVD). Air pollution is also a major contributor to the excess risk of cardiovascular events in many regions of the world. However, little is known about the effect of individual-level mitigation strategies against air pollution in reducing cardiovascular outcomes. The purpose of the first randomization is to compare the efficacy and safety of enteric-coated versus plain low-dose (81 mg) aspirin formulations in a double-blind fashion. The second randomization compares a multifaceted intervention including one-page educational flashcard, cell phone text messages alerting participants on polluted days, recommending them to stay indoors or wear KN-95 facemasks provided by the study team in case of necessary outdoor activity, and recommendation to consume citrus fruits on polluted days versus usual care. Both randomization are powered for clinical outcomes and the results will inform practice.",[205,206,207,208,209,88,26],"Atherosclerotic Cardiovascular Disease","Coronary Artery Disease","Ischemic Heart Disease","Ischemic Stroke","Peripheral Arterial Disease",[211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240],"atherosclerosis","atherosclerotic cardiovascular disease","atherosclerotic arterial disease","atherosclerotic plaque","coronay artery disease","ischemic heart disease","atherosclerotic disease","ischemic stroke","peripheral arterial disease","carotid artery stenosis","carotid atherosclerosis","myocardial infarction","acute limb ischemia","bleeding","major bleeding","gastrointestinal bleeding","gastrointestinal ulcer","peptic ulcer disease","gastric ulcer","duodenal ulcer","dyspepsia","intracerebral hemorrhage","aspirin","acetylsalicylic acid","antithrombotic therapy","antithrombotic agents","antiplatelet agents","air pollution","cerebral hemorrhage","hemorrhage","2025-03-14",{"date":243,"type":37},"2025-03-19",{"date":245,"type":37},"2024-03-06",{"date":247,"type":20},"2027-03-30",{"name":249,"class":44},"Rajaie Cardiovascular Medical and Research Center",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":258,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":262,"briefSummary":264,"conditions":265,"keywords":268,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":45},"100561426","phase-2-evaluating-the-impact-of-39tertinat39-on-patients-with-atherosclerosis-related-cardiovascular-diseases-100561426","NCT06590012","Evaluating the Impact of 'Tertinat' on Patients with Atherosclerosis-Related Cardiovascular Diseases","Prospective, Double-blind, Comparative Randomized Placebo-controlled Multicenter Study Evaluating the Impact of Oral Administration of the Peroral Supplement "Tertinat" with Dosage of 330 Mg\u002Fday for Patients with Cardiovascular Diseases, the Cause of Which is Atherosclerosis, on the Background of Standard Treatment.","TERACAD","Inclusion Criteria:\n\n* Patients with cardiovascular disease disease of atherosclerotic origin, requiring hospitalization and treatment hospital conditions. Cardiovascular diseases may include the following nosology: Coronary heart disease; Atherosclerosis. Diseases include (and\u002For) atherosclerotic lesions of the coronary arteries, brachiocephalic arteries, limb arteries, renal arteries requiring surgical revascularization.\n* Patients who have undergone a complex of necessary by current standards for their disease instrumental and laboratory examinations, including ECG, severity assessment vascular stenosis (ultrasound, CT, angiography), including large arteries, brachiocephalic arteries, femoral arteries, biochemical blood test assessing the level of general cholesterol, triglycerides, lipoproteins low density, high lipoprotein density, glucose level.\n* Possibility of monitoring the patient - Possibility every 12 months call the patient for questioning and examination.\n* The patient has signed informed consent.\n\nExclusion Criteria:\n\n* Critical and urgent cardiovascular conditions: tissue ischemia stage III-IV, stroke, acute coronary syndrome, myocardial infarction, chronic heart failure III and IV class NYHA (New York Heart Association).\n* Other critical and urgent conditions not associated with cardiovascular diseases, including the need for urgent interventions, chronic renal failure stages IV-V (creatinine clearance \\\u003C 30 ml \u002F min according to the Cockcroft-Gault Equation)\n* Systemic autoimmune diseases in medical history, including: rheumatoid arthritis, systemic lupus erythematosus, autoimmune thyroiditis, autoimmune vasculitis, ulcerative colitis.\n* Significant weight loss (\\> 10% of body weight in the previous year) of unknown etiology.\n* Conditions that limit adherence to participation in the study (dementia, neuropsychiatric diseases, drug addiction, alcoholism, etc.).\n* Participation in other clinical studies (or use of investigational substances) within 3 months prior to study entry.\n* Carriers of HIV or viral hepatitis\n* Pregnancy or breast feeding\n* Refusal to participate in the study.","45 Years","75 Years",{"count":261,"type":20},556,[263],"PHASE2","The aim of this clinical trial is to evaluate whether the biologically active food supplement, Tertinat, can influence atherosclerosis progression in adults and improve the treatment outcomes of cardiovascular diseases. The study will assess the frequency of fatal and clinically significant cardiovascular events, monitored every 12 months following participants\\' inclusion in the trial.\n\nAdditionally, the trial will evaluate Tertinat's ability to prevent pro-atherogenic modification of lipoproteins and its impact on inflammatory activity. To this end, levels of desialylated low-density lipoproteins (LDL) and inflammatory markers in the blood will be monitored. Tertinat administration will occur alongside the standard therapy prescribed to patients based on their existing medical conditions.\n\nResearchers will compare the effects of the Tertinat supplement to a placebo (an identical-looking substance that does not contain the active supplement) to determine if Tertinat is effective in reducing cardiovascular events .\n\nParticipants will:\n\nTake either Tertinat or a placebo daily for a duration of 24 months. Visit the clinic once a year for check-ups and testing.",[266,267,26],"Atherosclerosis","Atheroscleroses, Coronary",[211,269,270,221],"lipoproteins","coronary atherosclerosis","2024-09-06",{"date":273,"type":37},"2024-09-19",{"date":275,"type":37},"2024-08-29",{"date":277,"type":20},"2026-03-01",{"name":279,"class":44},"Institute for Atherosclerosis Research, Russia",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":45},"100556715","the-role-of-maintaining-external-carotid-artery-flow-in-graft-interposition-after-carotid-endarterectomy-100556715","NCT06528717","The Role of Maintaining External Carotid Artery Flow in Graft Interposition After Carotid Endarterectomy","AGICS","Inclusion Criteria:\n\n* symptomatic carotid stenosis (\\> 50%)\n* unilateral asymptomatic carotid stenosis (\\> 60%)\n* bilateral asymptomatic carotid stenosis (\\> 60%)\n\nExclusion Criteria:\n\n* carotid restenosis\n* \"major surgery\" in previous 6 months\n* previous brain trauma or surgery\n* malignant disease\n* epilepsy\n* carotid artery aneurysm","50 Years","90 Years",{"count":290,"type":20},250,"Analyzing results of carotid graft interposition with and without flow preservation through external carotid artery after endarterectomy.",[87,61,26],"2024-07-25",{"date":295,"type":37},"2024-07-30",{"date":297,"type":37},"2024-06-12",{"date":299,"type":20},"2024-12-30",{"name":301,"class":44},"Institute for Cardiovascular Diseases Dedinje",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":21,"phases":312,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":45},"100555361","phase-3-carotid-artery-stenting-during-endovascular-treatment-of-acute-stroke-100555361","NCT06511089","Carotid Artery Stenting During Endovascular Treatment of Acute Stroke","Carotid Artery Stenting During Endovascular Treatment of Acute Ischemic Stroke: A Randomized Multicenter Clinical Trial in Patients With Acute Ischemic Stroke and Carotid Artery Stenosis Undergoing Endovascular Treatment","CASES","Inclusion Criteria:\n\n1. Acute ischemic stroke due to proximal intracranial occlusion in the anterior circulation (intracranial ICA, M1, proximal M2) on the CT angiography\n2. Stenosis \\>50% according to the NASCET criteria16 or initial occlusion of the ipsilateral cervical carotid artery of presumed atherosclerotic origin on baseline CT angiography\n3. Eligible for EVT according to the guidelines: EVT within 6 hours of onset or EVT between 6-24 hours after onset based on perfusion CT imaging selection (conform current guidelines)\n4. Baseline National Institute of Health Stroke Scale (NIHSS) score ≥2\n5. Age \\>18 years\n6. Written informed consent (deferred consent)\n\nExclusion Criteria:\n\n1. Any intracranial hemorrhage\n2. Cervical carotid artery stenosis or occlusion with other causes than presumed atherosclerosis (e.g. carotid artery dissection, floating thrombus, carotid web)\n3. Any exclusion criterion for EVT according to the guidelines\n4. Pre stroke disability (defined as a modified Rankin Scale score \\>2)\n5. Recent gastro-intestinal or urinary tract hemorrhage (\\\u003C6 weeks)\n6. Recent severe head trauma (\\\u003C6 weeks)\n7. Recent infarction on baseline brain CT in the same vascular territory (\\\u003C6 weeks)\n8. Known allergy to aspirin and\u002For clopidogrel\n9. Pregnancy",{"count":311,"type":20},600,[313],"PHASE3","Rationale: Approximately 20% of the patients with acute ischemic stroke due to an intracranial large vessel occlusion (LVO) has a high-grade stenosis in the ipsilateral cervical carotid artery. It is uncertain whether immediate carotid artery stenting (CAS) of a cervical carotid artery stenosis during endovascular thrombectomy (EVT) is beneficial. Immediate CAS could improve cerebral perfusion and prevent recurrent ischemic stroke but could also increase the chance of intracranial hemorrhagic complications due to hyperperfusion syndrome or to the required antiplatelet treatment to prevent stent occlusion. Moreover, some patients end up with a severe disabling stroke after EVT. In these patients carotid revascularization by carotid endarterectomy (CEA) or CAS would usually not be performed but these patients would be treated by medical management only.\n\nObjective: to assess the safety and efficacy of immediate cervical CAS during EVT in patients with acute ischemic stroke due to LVO with a high-grade stenosis \\>50% or occlusion of the ipsilateral cervical carotid artery.\n\nStudy design: prospective randomized open label controlled trial comparing immediate CAS during EVT versus EVT with deferred treatment of the cervical carotid artery lesion (deferred CAS\u002FCEA or medical management alone). Outcome assessment will be blinded for treatment allocation.",[316,317,91,26,318],"Stroke, Acute","Stroke, Ischemic","Carotid Occlusion","2024-07-15",{"date":321,"type":37},"2024-07-19",{"date":323,"type":37},"2022-11-15",{"date":325,"type":20},"2026-11-15",{"name":327,"class":44},"University Medical Center Groningen",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":335,"maxAge":288,"enrollmentInfo":336,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":45},"100535602","carotid-atherosclerosis-in-predicting-coronary-artery-disease-100535602","NCT06253962","Carotid Atherosclerosis in Predicting Coronary Artery Disease","CACA","Inclusion Criteria:\n\n* patients receive carotid ultrasound and coronary angiography\n\nExclusion Criteria:\n\n* None","14 Years",{"count":337,"type":20},1000,"Carotid plaque burden and composition features, particularly lipid necrotic core, are significantly associated with severity of CAD stenosis. This study aims to explore the relationship between various phenotypic patterns of carotid atherosclerosis with the prevalence, phenotype, and severity of coronary atherosclerosis. The patients with chest tightness or chest pain will receive carotid artery ultrasonography before coronary angiography so as to explore the relationship between them.",[26,340],"Coronary Atheroscleroses","2024-02-04",{"date":343,"type":37},"2024-02-12",{"date":345,"type":20},"2024-02-10",{"date":347,"type":20},"2028-12-31",{"name":349,"class":44},"Shanghai Zhongshan Hospital"]